BioMarin
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
BMRN Key Statistics
BMRN News
Investors in BioMarin Pharmaceutical Inc. ( ) had a good week, as its shares rose 6.7% to close at US$68.73 following the release of its full-year results. BioM...
Analyst Whitney Ijem of Canaccord Genuity maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $84.00. Discover...
Analyst Yun Zhong of Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), retaining the price target of $94.00. Discover the Be...
Analyst ratings
79%
of 28 ratingsMore BMRN News
On Wednesday, BioMarin Pharmaceutical Inc. BMRN reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of...
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price targ...
Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on BMRN stock, giving a Buy rating today. Discover the Best Stocks and Ma...
Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $126 from $122 and keeps an Overweight rating on the shares following a Q4 top- and bottom-li...
Reports Q4 revenue $747M, consensus $711.05M. “Our operational transformation and strong financial execution in 2024 is the first step in BioMarin’s (BMRN) ambi...